English
Bulgarian
Chinese (Simplified)
Croatian
Czech
Danish
Dutch
Finnish
French
German
Greek
Hebrew
Hindi
Indonesian
Italian
Japanese
Korean
Macedonian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swedish
Thai
Turkish
Vietnamese
iCMLf Run.Ride.Cure 2020 - Wall of Fame
This year the annual John Goldman charity run was virtual. With the help of 16 dedicated participants, including; previous preceptors, CML patients, colleagues and supporters - among them a six year old and an eight year old - we have raised more than $9,200 through the iCMLf Run.Ride.Cure 2020.
Thanks to everyone for their contributions!
CML Publications 2019
| Clinical Publications | Scientific Publications |
| December 2019 | |
| Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEA CML WP (Baccarani M et al. Blood Adv. December, 2019) – open access publication |
Comprehensive analyses of safety and efficacy towards individualizing imatinib dosage in patients with chronic myeloid leukemia (Shin H et al. Int J Hematol, December 2019) (epub ahead of print) |
| Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in CML study (Soverini S et al. Blood, December 2019) (epub ahead of print) |
A novel inhibitor of STAT5 signaling overcomes chemotherapy resistance in myeloid leukemia cells (Brachet-Botineau M et al. Cancers (Basel), December 2019) |
| Tyrosine kinase inhibitors in leukemia and cardiovascular events: From mechanisms to patient care (Manouchehri A et al. Arterioscler Thromb Vasc Bio, December 2019) (epub ahead of print) – open access publication |
Marrow fibrosis is an independent predictor of hematological toxicity of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia (Ni J et al. Leuk Lymphoma, December 2019) (epub ahead of print) |
|
Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia |
Reconstituion of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation |
| Feasibility study of switching to nilotinib after first-line imatinib in the chronic phase of chronic myeloid leukemia (Chen Y et al. Clin Lymphoma Myeloma Leuk, December 2019) |
Macrophage protects mycoplasma-infected chronic myeloid leukemia cells from NK cell killing (Choo QWW et al. Immunol Cell Biol, December 2019) (epub ahead of print) |
| Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure (Hughes TP et al. N Eng J Med, December 2019) |
Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper (Soverini S et al. J Hematol Oncol, December 2019) - OPEN ACCESS |
| Do persons with chronic myeloid leukemia have normal or near normal survival? (Radivoyevitch T et al. Leukemia, December 2019) (epub ahead of print) - OPEN ACCESS |
Chronic myeloid leukemia: The danger of not knowing your BCR-ABL1 transcript (Sharplin K et al. Leuk Res, December 2019) |
| Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: An update (Bavaro L et al. Int J Mol Sci, December 2019) - OPEN ACCESS |
Preclinical development of a novel BCR-ABL T315I inhibitor against chronic myeloid leukemia (Gupta P et al. Cancer Lett, December 2019) (epub ahead of print) |
| Utility of therapeutic drug monitoring of imatinib, nilotinib, and dasatinib in chronic myeloid leukemia: A systematic review and meta-analysis (García-Ferrer M et al. Clin Ther, December 2019) |
The predictive value of intracellular imatinib levels in newly diagnosed chronic myeloid leukemia (Hillis S et al. Leuk Res, December 2019) (epub ahead of print) |
| Treatment-free remission in chronic myeloid leukemia (Molica M et al. Clin Adv Hematol Oncol, December 2019) |
Blast crisis of chronic myeloid leukemia with plasmacytoid dentritic cell phenotype associated with a rare fusion transcript, e13a3 BCR-ABL1 (Xu D et al. Leuk Lymphoma, December 2019) |
| Management of ponatinib in patients with chronic myeloid leukemia with cardiovascular risk factors (Santoro M et al. Chemotherapy, December 2019) (epub ahead of print) |
|
| November 2019 | |
| Sudden blastic transformation in treatment-free remission chronic myeloid leukemia (Alfayez M et al. Br J Haematol, November 2019) |
Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission |
| New approaches to molecular monitoring in CML (and other diseases) (Radich J et al. Blood, November 2019) |
Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Lauseker M et al. Am J Hematol, November 2019) |
|
Compexity of chronic-phase CML management after failing a second-generation TKI |
Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells (Tanaka A et al. J Exp Med, November 2019) (epub ahead of print) |
| Towards a personalized treatment of patients with chronic myeloid leukemia (Rabian F et al. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
Role of cancer immunology in chronic myelogenous leukemia (Ureshino H et al. Leuk Res, November 2019) (epub ahead of print) |
| The TKI-free duration after a first discontinuation attempt that failed in CP CML patients is a predictive factor of TKI-free remission after a second attempt (Legros L et al. Blood, November 2019) |
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315l clones in TKI-resistant CML (Schneeweiss-Gleixner M et al. EBioMedicine, November 2019) (epub ahead of print) |
| Prognostication of molecular relapses after dasatinib or nilotinib discontinuation in chronic myeloid leukemia (CML): A FI-LMC STOP 2G-TKI study update (Rea D et al. Blood, November 2019) |
Repurposing drugs in silico methods to target BCR kinase domain in chronic myeloid leukemia (Natarjan A et al. Asian Pac J Cancer Prev, November 2019) http://journal.waocp.org/article_88830.html |
| Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also bEarly management of CML (Shanmunagathan N et al. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
Druggable biochemical pathways and potential therapeutic alternatives to target leukemia stem cells and eliminate the residual disease in chronic myeloid leukemia |
| Introducing a predictive score for successful treatment-free remission in chronic myeloid leukemia (CML) (Claudiani S et al. Blood, November 2019) |
Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia (Lernoux M et al. Biochem Pharmacol, November 2019) (epub ahead of print) |
|
Early management of CML |
The hidden pathogenesis of CML: Is BCR-ABL1 the first event? (Shanmunagathan N, Branford S. Curr Hematol Malig Rep, November 2019) (epub ahead of print) |
| October 2019 | |
| Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia (Franke GN et al. J Mol Diagn, October 2019) (epub ahead of print) |
Combining the allosteric inhibitor asciminib with ponatinib suppresses emergence of and restores efficacy against highly resistant BCR-ABL1 mutants (Eide CA et al. Cancer Cell, October 2019) |
| Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study (Shah NP et al. Leuk Lymph, October 2019) (epub ahead of print) |
|
| Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type (Baccarani et al. Leukemia, October 2019) |
|
| September 2019 | |
| Prolonged treatment free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations (Claudiani S et al. Haematologica, September 2019) (epub ahead of print) |
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Magistroni V et al. Haematologica, September 2019 |
| Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia (Naqvi K et al. Cancer, September 2019) (epub ahead of print) |
Efficacy of dasatinib against ponatinib-resistant chronic myeloid leukemia cells (Okabe S et al. Leuk Lymphoma, September 2019) (epub ahead of print) |
| New approaches of molecular monitoring in CML (and other diseases) (Radich J et al. Blood, September 2019) (epub ahead of print) |
KLF4 represses DYRK2 inhibition of self-renewal and survival through c-Myc and p53 in leukemia stem/progenitor cells (Park CS et al. Blood, September 2019) (epub ahead of print) |
| Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy (Efficace F et al. Leukemia, September 2019) (epub ahead of print) |
MiR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation (Huang T et al. Biomed Pharmacother, September 2019) (epub ahead of print) |
| Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt) (Nagafuji K et al. J Hematol, September 2019) (epub ahead of print) |
The dynamic of TNF and IL6 gene expression in chronic myeloid leukemia patients reveals early responders to imatinib (Bestach Y et al. Leuk Res, September 2019) (epub ahead of print) |
| Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy (Tiribelli M et al. Ann Hematol, September 2019) |
The interaction of tumor cells and myeloid-derived suppressor cells in chronic myelogenous leukemia (Xu H et al. Leuk Lymphoma, September 2019) (epub ahead of print) |
| Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States (Abou Dalle I et al. Cancer Med, September 2019) (epub ahead of print) |
|
| Tyrosine kinase inhibitors in the clinical setting: A conundrum of choices (Bankar A et al. Acta Haematol, September 2019) |
|
|
Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial |
|
| August 2019 | |
| Prognosis of patients with chronic myeloid leukemia presenting in advanced phase is defined mainly by blast count, but also by age, chromosomal aberrations and hemoglobin (Lauseker M et al. Am J Hematol, August 2019) (epub ahead of print) |
BCR-ABL1- and CBFB-MYH11-positive chronic myeloid leukemia presenting with primary blast crisis and marrow fibrosis (Kidoguchi K et al. Ann Hematol, August 2019) (epub ahead of print) |
| Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type (Baccarani M et al. Leukemia, August 2019) (epub ahead of print) |
Continuous cytostatic effects of BCR-ABL tyrosine kinase inhibitors (TKI’s) after washout in human leukemic K562 cells (Aoyama T et al. Biol Pharm Bull, August 2019) (epub ahead of print) |
| Treatment patterns and deep molecular response in chronic-phase – chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, August 2019) (epub ahead of print) |
Identification of key candidate targets and pathways for the treatment of leukemia using bioinformatics analysis (Li H et al. Mol Genet Genomic Med, August 2019) (epub ahead of print) |
| Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukemia (Ross DM et al. Br J Haematol, August 2019) |
Bone marrow microenvironment: The guardian of leukemia stem cells (Houshmand M et al. World J Stem Cells, August 2019) |
| Treatment patterns and deep molecular response in chronic phase chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: a multi-country retrospective chart review study (Cortes J et al. Leuk Lymphoma, August 2019) (epub ahead of print) |
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of surviving and cyclin D1 in chronic myeloid leukemia cells (Moriyama K et al. Int J Hematol, August 2019) (epub ahead of print) |
| Discontinuation of tyrosine kinase inhibitors in patients with chronic myelogenous leukemia – You can do this if you read the instructions (Schiffer CA. Haematologica, August 2019) |
Combined inhibition of MDM2 and BCR-ABL tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model (Carter BZ et al. Haematologica, August 2019) (epub ahead of print) |
| The efficacy of tolvaptan in treating dasatinib-induced pleural effusions in patients with chronic myelogenous leukemia (Aoyama R et al. J Cardiol, August 2019) (epub ahead of print) |
Phosphorylation of Beclin-1 by BCR-ABL suppresses autophagy in chronic myeloid leukemia (Yu C et al. Haematologica, August 2019) (epub ahead of print) |
| Nilotinib efficacy, safety, adherence and impact on quality of life in newly diagnosed patients with chronic myeloid leukemia in chronic phase: a prospective observational study in daily clinical practice (Huguet F et al. Br J Haematol, August 2019) (epub ahead of print) |
BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of surviving and Cyclin D1 in chronic myeloid leukemia cells (Moriyamo K et al. Int J Hematol, August 2019) (epub ahead of print) |
| Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in real-life practice (Caocci G et al. Ann Hematol, August 2019) |
Targeting small molecule tyrosine kinases by Polyphenols: New move towards anti-tumor drug discovery (Sakle NS et al. Curr Drug Discov Technol, August 2019 (epub ahead of print) |
| New approaches and treatment combinations for the management of chronic myeloid leukemia (Westerweel PE et al. Front Oncol, August 2019) |
|
| FISH versus real-time quantitative PCR for monitoring of minimal residual disease in chronic myeloid leukemia patients with tyrosine kinase inhibitor therapy (Haidary AM et al. Malays J Pathol, August 2019) |
|
| Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase exposure: A Blood or Marrow transplant Survivor Study (BMTSS) Report (Wu J et al. Cancer, August 2019) (epub ahead of print) |
|
| Outcome of very elderly chronic myeloid leukemia patients treated with imatinib frontline (Crugnola M et al. Ann Hematol, August 2019) (epub ahead of print) |
|
| Recommendations from a Portuguese expert group for discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia patients in clinical practice (Almeida A et al. Acta Med Port, August 2019) (epub ahed of print) |
|
| July 2019 | |
| Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome (Berger MG et al. Br J Haematol, July 2019) (epub ahead of print) |
Oncurrence of chromosomal abnormalities in Philadelphia chromosome-negative metaphases in patients with chronic-phase chronic myeloid leukemia undergoing TKI treatments (Sheng G et al. Leuk Lymphoma, July 2019) (epub ahead of print) |
| Incidence and outcome of BCR-ABL mutated chronic myeloid leukemia patients who failed to tyrosine kinase inhibitors (Etienne G et al. Cancer Med, July 2019) (epub ahead of print) |
Targeting BCR-ABL 1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation (Burslem GM et al. Cancer Res, July 2019) (epub ahead of print) |
| Evaluation of residual disease and TKI duration are predictive factors for molecular recurrence after stopping imatinib first-line in chronic phase CML patients (Nicolini FE et al. Clin Cancer Res, July 2019) (epub ahead of print) |
Killer immunoglobulin-line receptor genotypes and chronic myeloid leukemia outcomes after imatinib cessation for treatment-free remission (Dumas PY et al. Cancer Med, July 2019) (epub ahead of print) |
| Clinical efficacy and safety of first-line nilotinib therapy and evaluation of the clinical utility of the FRET-based drug sensitivity test (Kondo T et al. Int J Hematol, June 2019) (epub ahead of print) |
Infliximab together with tyrosine kinase inhibition targets leukemic stem cells in chronic myeloid leukemia (Herrmann O et al. BMC Cancer, July 2019) |
| Digital droplet PCR at the time of TKI discontinuation in chronic phase chronic myeloid patients is predictive of treatment-free remission outcome (Colafigli G et al. Hematol Oncol, July 2019) (epub ahead of print) |
Human BCR-ABL1 induces chronic myeloid leukemia-like disease in zebrafish (Xu M et al. Haematologica, July 2019) (epub ahead of print) |
| True value of second-generation TKI’s as first-line therapy in chronic myeloid leukemia (Andrews CN et al. Lancet Haematol, June 2019) (epub ahead of print) |
Clinical characteristics and prognostic significance of chronic myeloid leukemia with rare BCR-ABL1 transcripts (Xue M et al. Leuk Lymphoma, July 2019) (epub ahead of print) |
| Front-line use of tryrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations (Reff MJ et al. J Oncol Pharm Pract, July 2019) (epub ahead of print) |
Determination of serum imatinib and it’s metabolite in patients with chronic myeloid leukemia (Onmaz DE et al. Clin Chim Acta, July 2019) (epub ahead of print) |
| Tyrosine kinase inhibitors available for chronic myeloid leukemia: Efficacy and safety (García-Gutiérrez V et al. Front Oncol, July 2019) |
The NEDD8-activating enzyme inhibitor MLN4924 induces DNA damage in PH+ leukemia and sensitizes for ABL kinase inhibitors (Bahjat M et al. Cell Cycle, July 2019) (epub ahead of print) |
| Differences in treatment and monitoring of chronic myeloid leukemia with regard to age, but not sex: results from a population-based study (Lauseker M et al. Eur J Haematol, July 2019) (epub ahead of print) |
Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/line cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment (Trojani A et al. PLoS One, July 2019) (epub ahead of print) |
| Comparison of BCR-ABL transcript variants between patients with chronic myeloid leukemia and leukemia cell lines (DE Oliveira Sales L et al. In Vivo, July-Aug 2019) |
|
| June 2019 | |
|
Neurotoxic events associated with BCR-ABL1 tyrosine kinase inhibitors: a case series |
SIRT1 regulates metabolism and leukemogenic potential in CML stem cells (Abraham A et al. J Clin Invest, June 2019) |
| De-escalation of tyrosine kinase inhibitor therapy before complete treatment discontinuation in patients with chronic myeloid leukemia (DESTINY): a non-randomized, phase 2 trial (Clark RE et al. Lancet Haematol, June 2019) (epub ahead of print) |
Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay. Is dPCR the key? (Bernardi S et al. Eur J Haematol, June 2019) (epub ahead of print) |
| Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukemia: a modeling study (Shih YT et al. Lancet Haematol, June 2019) (epub ahead of print) |
Knockdown of ribonucelotide reductase regulatory subunit M2 increases the drug sensitivity of chronic myeloid leukemia to imatinib-based therapy (Liu C et al. Oncol Rep, June 2019) (epub ahead of print) |
| Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia (Dragani M et al. Leuk Lymphoma, June 2019) (epub ahead of print) |
Clinical implications of simultaneous occurrence of variant Philadelphia translocations in chronic myeloid leukemia (Trivedi P et al. J Assoc Genet Technol, 2019) |
| Therapy de-escalation before stopping in chronic myeloid leukemia (Mustjoki S et al. Lancet Haematol, June 2019) (epub ahead of print) |
|
| Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy (Dou X et al. Oncologist, June 2019) (epub ahead of print) |
|
| Is there a role for dose modification of TKI therapy in CML? (Copland M. Curr Hematol Malig Rep, June 2019) (epub ahead of print) |
|
| May 2019 | |
| NCCN Guidelines updates: Discontinuing TKI therapy in the treatment of chronic myeloid leukemia (Shah NP et al. J Natl. Compr Canc Netw, May 2019) |
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib (Kok CH et al. Blood Adv, May 2019) |
| Can Chronic-Phase Chronic Myeloid Leukemia Patients Achieve Optimal and Durable Responses after Two Failed TKI Treatments? Real-World Evidence Data (Breccia M et al. Acta Haematol, May 2019) (epub ahead of print) |
Outcomes of patients with chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy (Boddu P et al. Leuk Lymphoma, May 2019) (epub ahead of print) |
| Ten-year outcome of chronic-phase chronic myeloid leukemia patients treated with imatinib in real life (Molica M et al. Ann Hematol, May 2019) (epub ahead of print |
Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second generation tyrosine kinase inhibitors (Nteliopoulos G et al. Haematologica, May 2019) (epub ahead of print) |
| Patients’ perspective on the definition of cure in chronic myeloid leukemia (Flynn KE et al. Leuk Res, May 2019) |
The proportion of different transcript types in chronic myeloid leukemia: An international review (Baccarani M et al. Leukemia, May 2019) |
| Risk and outcomes of second malignant neoplasms in chronic myeloid leukemia survivors (Jamy O et al. Leuk Res, May 2019) (epub ahead of print) |
Precision tyrosine kinase inhibitor dosing in chronic myeloid leukemia |
| Current outlook on drug resistance in chronic myeloid leukemia (CML) and potential therapeutic options (Sundaram DNM et al. Drug Discov Today, May 2019) (epub ahead of print) |
Digital PCR in myeloid malignancies: Ready to replace quantitative PCR? |
| Influence of glutathione S-transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response (Rostami G et al. Mol Genet Genomic Med, May 2019) (epub ahead of print) |
|
| Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo (Jyotsana N et al. Ann Hematol, May 2019) (epub ahead of print) |
|
| Validation of a Drosophila model of wild type and T315l mutated BCR-ABL1 in chronic myeloid leukemia: An effective platform for treatment screening (Al Outa A et al. Haemotologica, May 2019) (epub ahead of print) |
|
| PF-114, a novel selective inhibitor of BCR-ABL tyrosine kinase, is a potent inducer of apoptosis in chronic myelogenous leukemia cells (Ivanova ES et al. Int J Oncol, May 2019) (epub ahead of print) |
|
|
|
Chronic myeloid leukemia stem cells |
| April 2019 | |
| A phase 2 study of alpha interferon for molecularly measurable residual disease in chronic myeloid leukemia after allogeneic hemotopoietic cell transplantation (Bezerra ED et al. Leuk Lymphoma, April 2019) |
Antitumor efficacy of arsenal/interferon in preclinical models of chronic myeloid leukemia resistant to tyrosine kinase inhibitors |
| The outcomes of chronic myeloid leukemia patients with molecular warning responses during imatinib treatment according to the European LeukemiaNet 2013 recommendations (Soysal T et al. Clin Lymphoma Myeloma Leuk, April 2019) (epub ahead of print) |
The vascular bone marrow niche influences outcomes in chronic myeloid leukemia via the E-selectin-SCL/TAL1-CD44 axis |
| Patient-reported outcomes in the phase 2 BEFORE trial of bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia (Cortes JE et al. J Cancer Res Clin Oncol, April 2019) (epub ahead of print) |
Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission (Shanmuganathan N et al. Blood, April 2019) (epub ahead of print) |
| Matching-adjusted indirect comparison of bosutinib, dasatinib, and nilotinib on survival and major cytogenetic response for treatment of second-line chronic phase chronic myeloid leukemia (Cortes JE et al. Curr Med Res Opin, April 2019) (epub ahead of print) |
Compound mutations in CML – imaginary bogeyman or real arch-nemesis? (Yeung DT. Leuk Res, April 2019) |
|
Exploring patient decision making regarding discontinuation of tyrosine kinase inhibitors for chronic myeloid leukemia |
Variant specific discrepancy when quantitating BCR-ABL1 e13a2 and e14a2 transcripts using the Europe against cancer qPCR assay |
| Results of the European survey on the assessment of deep molecular response in chronic phase CML patients during tyrosine kinase inhibitor (Möbius S et al. J Cancer Res Clin Oncol, April 2019) (epub ahead of print) |
Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia (Wang R et al. Medicine, April 2019) |
|
Anthropometric facts and risk of myeloid leukaemias and myelodysplastic syndromes: a prospective study and meta-analysis |
|
| March 2019 | |
| MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia (Claudiani S et al. Haematologica, March 2019) (epub ahead of print) |
Discovery and characterization of a novel highly potent and selective type II native and drug-resistant V299L mutant BCR-ABL inhibitors (CHMFL-ABL-039) for Chronic Myeloid Leukemia (CML) (Wu J et al. Cancer Biol Ther, March 2019) (epub ahead of print) |
|
Lenalidomine maintenance after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukemia |
Rates of deep molecular response by digital and conventional PCR with frontline nilotinib in newly diagnosed chronic myeloid leukemia: a landmark analysis |
| Nilotinib in the treatment of chronic myeloid leukemia (Sacha T et al. Future Oncol, March 2019) |
TOPK is regulated by PP2A and BCR/ABL in leukemia and enhances cell proliferation (Uchida E et al. Int J Oncol, March 2019) (epub ahead of print) |
| Analysis of cardiovascular and arteriothrombotic events in chronic-phase CML patients after frontline TKI’s (Jain P et al. Blood Adv, March 2019) |
A synergistic combination against chronic myeloid leukemia: An intra-molecular mechanism of communication in BCR-ABL1 resistance (El Rashedy AA et al. Protein J, March 2019) (epub ahead of print) |
| Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (Score) chart (Caocci G et al. Hematol Oncol, March 2019) (epub ahead of print) |
Stem cell persistence in CML is mediated by extrinsically activated JAK1-STAT3 signaling (Kuepper MK et al. Leukemia, March 2019) (epub ahead of print) |
| Skeletal muscle toxicity associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia (Janssen L et al. Leukemia, March 2019) (epub ahead of print) |
Impact of additional chromosomal aberrations on the disease progression of chronic myelogenous leukemia (Krishna Chandran R et al. Front Oncol, March 2019) (epub ahead of print) |
| Incidence of second malignancies in patients with chronic myloid leukemia in the era of tyrosine kinase inhibitors (Sasaki K et al. Int J Hematol, March 2019) (epub ahead of print) |
Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact an inclusion of CML patients in stopping trials (Spiess B et al. PLos One, March 2019) |
| Novel tyrosine kinase inhibitors for patients with inadequate response in chronic myeloid leukemia (Mauro MJ. Curr Opin Hematol, March 2019) |
Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review) (Lee HR et al. Oncol Rep, March 2019) (epub ahead of print) |
|
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities |
|
|
Can increased immunogenicity in chronic myeloid leukemia improve outcomes? |
|
|
Can increased immunogenicity in chronic myeloid leukemia improve outcomes? |
|
| February 2019 | |
| Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice (Fava C et al. Haematologica, February 2019) (epub ahead of print) |
De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways (Magistroni V et al. Haematologica, February 2019) (epub ahead of print) |
| Bone marrow fibrosis associated with long-term imatinib therapy: resolution after switching to a second-generation TKI (Shanmunagathan N et al. Blood Adv, February 2019) |
Single nucleotide polymorphism in PTEN-Long gene: A risk factor in chronic myeloid leukemia (Ferri C et al. Gene, February 2019) (epub ahead of print) |
| Impact of second decline rate of BCR-ABL1 transcript on clinical outcome of chronic phase chronic myeloid leukemia patients on imatinib first-line (Dulucq S et al. Ann Hematol, February 2019) (epub ahead of print) |
PTBP2 exon 10 inclusion is associated with the progression of CML and it is BCR-ABL 1 dependent (Nandagopalan SR et al. Int J Biochem Cell Biol, February 2019) (epub ahead of print) |
| Chronic myeloid leukaemia in pregnancy: call for guidelines (Pallavee P et al. J Obste Gynaecol, February 2019) (epub ahead of print) |
Analysis of major BCR-ABL1 mRNA by digital polymerase chain reaction is useful for prediction of international scale (Furuya D et al. Int J Clin Oncol, February 2019) (epub ahead of print) |
|
The spectrum of musculoskeletal symptoms in patients with chronic myeloid leukemia after stopping tyrosine kinase inhibitors |
Imatinib treatments have long-term impact on placentation and embryo survival (Salem W et al. Sci Rep, February 2019) |
| Everolimus in combination with imatinib overcomes resistance in chronic myeloid leukemia (Alves R et al. Med Oncol, February 2019) |
Novel mutations in the kinase domain of BCR-ABL gene causing imatinib resistance in chronic myeloid leukemia patients |
|
Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis |
High circ_100053 predicts a poor outcome for chronic myeloid leukemia and is involved in imatinib resistance (Ping L et al. Oncol Res, February 2019) |
| Efficacy and safety of tyrosine kinase inhibitors for newly myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system (Kizaki M et al. Int J Hematol, February 2019) (epub ahead of print) |
MiR-378 promoted cell proliferation and inhibited apoptosis by enhance stem cell properties in chronic myeloid leukemia K562 cells |
| January 2019 | |
| Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib (Latifi Y et al. Blood, January 2019) (epub ahead of print) |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: An international overview (Baccarani M et al. Leukemia, January 2019) (epub ahead of print) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (Chamoun K et al. J Hematol Oncol, January 2019) |
Prediction of ALK mutations mediating ALK-TKI’s resistance and drug re-purposing to overcome the resistance (Okada K et al. E-Bio Medicine, January 2019) (epub ahead of print) |
| The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia (Lasica M et al. Leuk Lymphoma, January 2019) (epub ahead of print) |
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia: An international overview (Baccarani M et al. Leukemia, January 2019) (epub ahead of print) |
| Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience (Chamoun K. J Hematol Oncol, January 2019) |
New tool for monitoring molecular response in patients with chronic myeloid leukemia (Badar T et al. Appl Immunohistochem Mol Morphol, January 2019) |
|
Thrombotic microangipathy as a cause for cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib |
NKG2A down-regulation by dasatinib enhances natural killer cytotoxicity and accelerates effective treatment responses in patients with chronic myeloid leukemia (Chang MC et al. Front immunol, January 2019) |
|
Long-term disease control in chronic myeloid leukemia |
A novel naphtoquine-coumarin hybrid that inhibits BCR-ABL1-STAT5 oncogenic pathway and reduces survival in imatinib-resistant chronic myelogenous leukemia cells (Martín-Rodríguez P et al. Front Pharmacol, January 2019) |
|
The case for real-world evidence in the future of clinical research on chronic myeloid leukemia |
Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia (Xie J et al. Oncol Lett, January 2019) |
| Risk and challenges of CML management during pregnancy: looking for a balanced decision (Chelysheva E et al. Eur J Haematol, January 2019) (epub ahead of print) |
Twins with two different personalities: STAT5B but nocht STAT5A has a key role in BCR/ABL-induced leukemia (Kollmann S et al. Leukemia, January 2019) (epub ahead of print) |
CML Publications 2018
| Clinical Publications | Scientific Publications |
| December 2018 | |
| Imatinib is still recommended for frontline therapy for CML (Hantel A et al. Blood Adv, December 2018Blood Adv, December 2018) |
A kinase profile-adapted drug combination elicits cooperative effects on leukemia cells carryging BCR-ABL1T315l in PH+ CML (Gleixner KV et al. Leuk Res, December 2018) (epub ahead of print) |
| Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review (Cortes JE et al. J Hematol Oncol, December 2018) |
Predictive models for designing potent tyrosine kinase inhibitors in chronic myeloid leukemia for understanding its molecular mechanism of resistance by molecular docking and dynamics simulations |
| A second-generation TKI should always be used as initial therapy for CML (Cortes JE. Blood Adv, December 2018) |
Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia (Bidet A et al. Haematologica, December 2018) (epub ahead of print) |
| Imatinib dose reduction in major molecular response of chronic myeloid leukemia: results from the German Chronic Myeloid Leukemia-Study IV (Michel C et al. Haematologica, December 2018) (epub ahead of print) |
|
|
Nilotinib in the treatment of chronic myeloid leukemia |
|
|
Cardiovascular risk and cardiovascular events in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors |
|
| November 2018 | |
| Molecular monitoring in CML: how deep? How often? How should it influence therapy? (Shanmuganathan N et al. Blood, November 2018) |
A modified DAW-22 compound F-B1 inhibits BCR-ABL and induces apoptosis in chronic myelogenous leukemia cells (Wang F et al. Anticancer Drugs, November 2018) (epub ahead of print) |
| Treatment-free remission with first- and second-generation tyrosine kinase inhibitors (Cortes J et al. Am J Hematol, November 2018) |
Genomic amplification of BCR-ABL1 fusion gene and its impact of the disease progression mechanism in patients with chronic myelogenous leukemia (Chandran RK et al. Gene, November 2018) (epub ahead of print) |
| The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study (Di Felice E et al. BMC Cancer, November 2018) |
To what extent can mathematical modeling inform the design of clinical trials? The example of safe dose reduction of tyrosine kinase inhibitors in responding patients with chronic myeloid leukemia (Schiffer JT et al. Haematologica, November 2018) |
| Back to the future: TFR and pregnancy in CML (Abruzzese E et al. Eur J Haematol, November 2018) (epub ahead of print) |
A new BCR-ABL1 Drosophilia model as a powerful tool to elucidate pathogenesis and progression of chronic myeloid leukemia (Bernardoni R et al. Haematologica, November 2018) (epub ahead of print) |
|
Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients (García-Gutiérrez V et al. Ann Hematol, November 2018)(epub ahead of print) |
Epigenetic regulation of HOTAIR in advanced chronic myeloid leukemia (Li Z et al. Cancer Manag Res, November 2018) |
| Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia (Klil-Drori AJ et al. Cancer, November 2018) (epub ahead of print) |
Chronic myeloid leukemia with complex karyothypes: Prognosis and therapeutic approaches (Asnafi AA et al. J Cell Physiol, November 2018) (epub ahead of print) |
| October 2018 | |
| Treatment-free remission after second-line nilotinib treatment (Mahon MX et al. Ann Intern Med, October 2018) |
Modeling ponatinib resistance in tyrosine kinase inhibitor naïve and dasatinib resistant BCR-ABL1+ cell lines (Lu L et al. Oncotarget, October 2018) |
| Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells (Ross DM et al. Leukemia, October, 2018) (epub ahead of print) |
A phase I clinical trial of ruxolitinib in combination with nilotinib in chronic myeloid leukemia patients with molecular evidence of disease (Sweet K et al. Leuk Res, October 2018) (epub ahead of print) |
| Adult leukemia survival trends in the United States by subtype: A population-based registry study of 370,994 patients during 1995-2009 (Bailey C et al. Cancer, October 2018) (epub ahead of print) |
Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: Assessment of potential value (Hidalgo-López JE et al. Cancer, October 2018) (epub ahead of print) |
| Early molecular response ≤ 1% has strong prognostic impact for CML patients that switch to second line therapy with BCR-ABL ≤ 10% and no major molecular response (Bonecker S et al. Br J Haematol, October 2018) (epub ahead of print) |
Alteration of cellular and immune-related properties of bone marrow mesenchymal stem cells and macrophages by K562 chronic myeloid leukemia cell derived exosomes (Jafarzadeh N et al. J Cell Physiol, October 2018) (epub ahead of print) |
| A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors (Zulbaran-Rojas A et al. Cancer Med, October 2018) (epub ahead of print) |
Optimized digital droplet PCR for BCR-ABL (Maier J et al. J Mol Diagn, October 2018) (epub ahead of print) |
| Treatment-free remission in patients with chronic myeloid leukemia (Rea D et al. Int J Hematol, October 2018) |
Clinical evaluation of massively parallel RNA sequencing for detecting recurrent gene fusion in hematologic malignancies (Kim B et al. J Mol Diagn, October 2018) (epub ahead of print) |
| Tyrosine kinase inhibitor interruptions, discontinuation and switching in patients with chronic-phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY (Hehlmann R et al. Ann J Hematol, October 2018) (epub ahead of print) |
Real-time qualitative PCR: a reliable molecular diagnostic and follow-up tool for ‘minimal residual disease’ assessment in chronic myeloid leukemia (Azad NA et al. Biosci Rep, October 2018) |
|
|
Searching for potential novel BCR-ABL tyrosine kinase inhibitors through G-QSAR and docking studies of some novel 2-phenazinamine derivates |
|
Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia |
|
| September 2018 | |
| Chronic myeloid leukemia relapsing 25 years after allogeneic stem cell transplantation (Reikvam H et al. Case Rep Hematol, September 2018) |
Ponatinib activates an inflammatory response in endothelial cells via ERK5 SUMOylation (Paez-Mayorga J et al. Front Cardiovasc Med, September 2018) |
| Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: The PEARL observational study (Heiblig M et al. Exp Hematol, September 2018) (epub ahead of print) |
Autophagy and mitochondrial metabolism: Insights into their role and therapeutic potential for chronic myeloid leukaemia (Baquero J et al. FEBS J, September 2018) (epub ahead of print) |
| Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib (Ottmann O et al. Blood Cancer J, September 2018) |
Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal (Toofan P et al. Cell Death Dis, September 2018) |
| Canadian chronic myeloid leukemia outcomes post-transplant in the tyrosine kinase era (Savoie ML. Leuk Res, September 2018) (epub ahead of print) |
Systematic review of pre-clinical chronic myeloid leukemia |
| Identifying tyrosine kinase inhibitor nonadherence in chronic myeloid leukemia: subanalysis of TAKE-IT pilot study (Clin Lymphoma Myeloma Leuk, September 2018) |
CircBA9.3 supports the survival of leukaemic cells by up-regulating C-ABL1 or BCR-ABL1 protein levels (Pan Y et al. Blood Cells Mol Dis, September 2018) (epub ahead of print) |
| Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology (Radich JP et al. J Natl. Compr Canc Netw, September 2018) |
Hydroxycoumarin OT-55 kills CML cells alone or in synergy with imatinib or Synribo: involvement of ER stress and DAMP release (Mazumder A et al. Cancer Lett, September 2018) (epub ahead of print) |
| Gene expression analysis of noncoding PCA3 gene in patients with chronic myeloid leukemia (Sajjadi E et al. J Cancer Res Ther, July-September 2018) |
|
| August 2018 | |
| Long-term follow-up of de novo chronic phase chronic myelogenous leukemia patients on front-line imatinib (Nicolini FE et al. Exp Hematol, August 2018) |
Development, function and clinical significance of plasmacytoid dentritic cells in chronic myeloid leukemia (Inselmann S et al. Cancer Res, August 2018) (epub ahead of print) |
| Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia (Hughes TH et al. Haematologica, August 2018) (epub ahead of print) |
Consensus of BCR-ABL-1 reporting in chronic myeloid leukemia in the UK (Cross NCP et al. Br J Haematol, August 2018) (epub ahead of print) |
| Impact of earlier versus later monitoring on disease progression and healthcare costs among patients with chronic myeloid leukemia in the United States (Jabbour EJ et al, August 2018) (epub ahead of print) |
The clinical outcomes of chronic myeloid leukemia patients harboring alternatively spliced BCR-ABL variants (Ishida T et al. Hematology, August 2018) (epub ahead of print) |
| Quantitative prediction of long-term molecular response in TKI-treated CML – Lessons from an imatinib versus dasatinib comparison (Glauche I et al. Sci Rep, August 2018) |
Evaluation of resistance to HIV-1 infection ex vivo of PBNCs isolated from patients with chronic myeloid leukemia treated with different tyrosine kinase inhibitors (Bermejo M et al. Biochem Pharmacol, August 2018) (epub ahead of print) |
| Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic-phase; the DASPERSE study (Kim DW et al. Ann Hematol, August 2018) |
Crosstalk between BCR-ABL and protease-activated receptor1 (PAR1) suggests a novel target in chronic myeloid leukemia |
| Imatinib through levels: a potential biomarker to predict cytogenetic and molecular response in newly diagnosed patients with chronic myeloid leukemia (Natarajan H et al. Leuk Lymphoma, August 2018) (epub ahead of print) |
Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL-1 |
| July 2018 | |
| Comparison of frequency and sensitivity of BCR-ABL1 kinase domain mutations in Asian and white patients with imatinib-resistant chronic-phase chronic myeloid leukemia (Kim H et al. Clin Lymphoma Myeloma Leuk, July 2018) (epub ahead of print) |
Single-molecule sequencing reveals patterns of pre-existing drug resistance that suggest treatment strategies in Philadelphia-positive leukemias (Schmitt MW et al. Clin Cancer Res, July 2018) (epub ahead of print) |
| Radotinib-induced eruptive melanocytic nevi in patient with chronic myeloid leukemia: a case report and literature review (Park E et al. Ann Hematol, July 2018) (epub ahead of print) |
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy |
| Chronic myeloid leukemia and pregnancy: patient and partner perspectives (Luskin MR et al. Expert Rev Hematol, July 2018) (epub ahead of print) |
BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia (Pagani IS et al. Haematologica, July 2018) (epub ahead of print) |
| Switches of tyrosine-kinase inhibitors in chronic phase of chronic myeloid leukemia in real life (Am J Hematol, July 2018) (epub ahead of print) |
Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease (Branford S et al. Blood, July 2018) (epub ahead of print) |
| Extended dose with CC-486 (oral azacitidine) in patients with myloid malignancies (Savona MR et al. Am J Hematol, July 2018) (epub ahead of print) |
Telomere shortening correlates with leukemic stem cell burden at diagnosis of chronic myeloid leukemia (Bouillon AS et al. Blood Adv, July 2018) |
|
|
A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML (Gopal S et al. Blood Adv, July 2018) |
| The underestimated role of basophils in PH+ CML (Valent P et al. Eur J Clin Invest, July 2018) |
|
| HDAC inhibitor suppresses proliferation and tumorigenicity of drug-resistant chronic myeloid leukemia stem cells through regulation of has-miR-196a targeting BCR/ABL1 (Bamodu OA et al. Exp Cell Res, July 2018) (epub ahead of print) |
|
| CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells (Wei XF et al. Cancer Cell Int, July 2018) |
|
| The potential of exosomes derived from chronic myelogenous leukemia cells as a biomarker (Kang KW et al. Anticancer Res, July 2018) |
|
| June 2018 | |
| Effect of adherence-enhancing interventions on adherence to tyrosine kinase inhibitor treatment in chronic myeloid leukemia (TAKE-IT): A quasi-experimental pre-post intervention multicenter pilot study (Leader A et al. Clin Lymphoma Myeloma Leuk, June 2018) (epub ahead of print) |
Past, present, and future of BCR-ABL inhibitors: from chemical development to clinical efficacy (Rossari F et al. J Hematol Oncol, June 2018) (Epub ahead of print) |
| The story of tyrosine kinase inhibitors discontinuation in clinical practice (Rousselot P. Leuk Lyphoma, June 2018) (epub ahead of print) |
Novel combined Ato-C treatment synergistically suppresses proliferation of BCR-ABL-positive leukemic cells in vitro and in vivo |
| Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: the younger, the later, the worse? (Latagliata R et al. Eur J Haematol, June 2018) |
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML (Brück O et al. Leukemia, June 2018) (epub ahead of print) |
| Upfront low-dose ponatinib (15mg/day) for multi-TKI resistant chronic myeloid leukemia (Tefferi A et al. Hematol Oncol, June 2018) |
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia (Zheng Y et al. Mol Med Rep, June 2018) (epub ahead of print) |
|
Present results and future perspectives in optimizing chronic myeloid leukemia therapy |
Chronic myelogenous leukemia on target (Némethová V et al. Cancer Med, June 2018) (epub ahead of print) |
|
Beyond maximum grade: modernizing the assessment and reporting of adverse events in haematological malignancies |
SiRNA/Lipopolymer nanoparticles to arrest growth of chronic myeloid leukemia cells in vitro and in vivo (Valencia-Serna J et al. Eur J Pharm Biopharm, June 2018) (epub ahead of print) |
|
Comparative analysis of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic myeloid leukemia following sub-optimal response to first-line imatinib |
|
| May 2018 | |
| Management of pregnancy in women with chronic myeloid leukemia (Ross D et al. J Clin Oncol, May 2018) (epub ahead of print) |
Experimental and integrative analyses identify an ETS1 network downstream BCR-ABL in chronic myeloid leukemia (CML) (Desterke C et al. Exp Hematol, May 2018) (epub ahead of print) |
| The evolution of dasatinib dosage over the years and its relevance to other anticancer medications (Schiffer CA et al. Cancer, May 2018) (epub ahead of print) |
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission (Bocchia M et al. Front Oncol, May 2018) |
|
Long-term follow-up of de novo chronic myelogenous leukemia patients on imatinib first-line |
Targeting BCR-ABL-independent TKI resistance in chronic myeloid leukemia by mTOR and autophagy inhibition (Mitchell R et al. J Natl Cancer Inst, May 2018) |
| Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia (Naqvi K et al. Cancer, May 2018) (epub ahead of print) |
Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells (Gover-Proaktor A et al. Leuk Lymphoma, May 2018) (epub ahead of print) |
| Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicenter, non-randomised trial (Saussele S et al. Lancet Oncology, May 2018) (epub ahead of print) |
Targeting HSP90 dimerization via the C-terminus is effective in imatinib resistant CML and lacks heat shock response (Bhatia S et al. Blood, May 2018) (epub ahead of print) |
| Reduced-dose imatinib in chronic-phase CML (Das M et al. Lancet Oncol, May 2018) (epub ahead of print) |
|
|
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study |
|
|
Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French chronic myeloid leukemia study group |
|
|
Pregnancy in patients with chronic myeloid leukemia |
|
|
Real-life experience with ponatinib in chronic myeloid leukemia: A multicenter observational study |
|
|
Breastfeeding in patients with chronic myeloid leukemia: Case series with measurements of drug concentrations in maternal milk and literature review |
|
| April 2018 | |
| Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia (Atallah E et al. BMC Cancer, April 2018) |
Validation of the EUTOS long-term survival score in a recent independent cohort of “real-world” CML patients (Geelen IGP et al. Leukemia, April 2018) |
|
Considerations of treatment-free remission in patients with chronic myeloid leukemia: A joint patient-physician perspective |
The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia (Spiess B et al. PLoS One, April 2018) |
|
Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic phase chronic myeloid leukemia |
Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia (Ruiz MS et al. Oncotarget, April 2018) |
|
Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia |
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients (Ricciardi MR et al. Oncotarget, April 2018) |
|
Ponatinib as second-line treatment in chronic-phase chronic myeloid leukemia patients in real-life practice |
Droplet digital PCR for BCR-ABL (P210) detecting of CML: A high sensitive method of the minimal residual disease and disease progression (Wang WJ et al. Eur J Haematol, April 2018) (epub ahead of print) |
| Aberrant DNA methylation of SOCS1 gene is not associated with resistance to imatinib mesylate among chronic myeloid leukemia patients (Elias MH et al. Cardiovasc Hematol Disord Drug Targets, April 2018) (epub ahead of print) |
|
| CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells (Huang SY et al. J Cell Physiol, April 2018) |
|
|
Wool-like hollow polymeric nanoparticles for CML chemo-combinatorial therapy |
|
| New rapid method to detect BCR-ABL fusion genes with multiplex RT-qPCR in one-tube at a time (Tong YQ et al. Leuk Res, April 2018) (epub ahead of print) |
|
| March 2018 | |
| Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial (Cortes JE et al. Blood, March 2018) (epub ahead of print) |
|
| Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib (Efficace F et al. Cancer, March 2018) (epub ahead of print) |
Bone marrow niche trafficking of MiR-126 controls the self-renewal of leukemia cells in chronic myelogenous leukemia (Zhang B et al. Nat Med, March 2018) (epub ahead of print) |
| Prediction of sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase (Sasaki K et al. Cancer, March 2018) |
Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy (Eadie LN et al. Leukemia, March 2018) (epub ahead of print) |
|
Safety and efficacy of nilotonib in routine clinical practice with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study |
Plasma and intracellular concentrations in an elderly patient with chronic myeloid leukemia receiving low-dose dasatinib therapy (Imamura M et al. Geriatr Gerontol Int, March 2018) |
|
Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report |
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemic cells (Mathew NR et al. Nat Med, March 2018) |
|
Novel tyrosine-kinase inhibitors for the treatment of chronic myeloid leukemia: safety and efficacy |
Targeting PFKFB3 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitor |
|
When to stop tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia |
|
|
Current information and recommendations on the discontinuation of TKI inhibitors in chronic myeloid leukemia |
|
| February 2018 | |
| Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV (Saussele S et al. Leukemia, February 2018) (epub ahead of print) |
|
|
Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic-myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the IIIb ENESTswift study |
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations |
|
Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study |
Effect of ABCG2, OCT1, and AB1 (MDR1) gene expression on treatment-free remission in a EURO-SKI subtrial (Rinaldetti S et al. Clin Lymphoma Myeloma Leuk, February 2018) (epub ahead of print) |
|
The cure of chronic myeloid leukemia: Are we there yet? |
Overexpression of TpK2 is linked to imatinib resistance and activation of MEK-ERK and NF-kB pathways in a model of chronic myeloid leukemia (Chorzalska A et al. Mol Oncol, February 2018) |
| Considerations for successful treatment-free remission in chronic myeloid leukemia (Goldberg SL et al. Clin Lymphoma Myeloma Leuk, February 2018) |
Therapy-free remission in chronic myeloid leukemia: possible mechanisms (Gale RP et al. Expert Rev Hematol, February 2018) |
| Chronic myelogenous leukemia: Pregnancy in the era of stopping tyrosine kinase inhibitor therapy (Berman E et al. J Clin Oncol, February 2018) (epub ahead of print) |
Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy (Soverini S et al. Mol Cancer, February 2018) |
| Identification of chronic myeloid leukemia patients treated with imatinib who are potentially eligible for treatment discontinuation by assessing real-life molecular response on the international scale in a EUTOS-certified lab (Heinrichs A et al. Leuk Res, February 2018) (epub ahead of print) |
Has-mir183/EGF-1 mediated regulation of E2F1 is required for CML stem/progenitor cell survival (Pellicano F et al. Blood, February 2018) (epub ahead of print) |
|
An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States |
Pharmacological inhibition of JAK3 enhances the antitumor activity of imatinib in human chronic myeloid leukemia |
|
Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing |
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia |
|
Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase |
Impact of SLC22A1 and CYP3A5 genotypes on imatinib response in chronic myeloid leukemia: A systematic review and meta-analysis
(Cargnin S et al. Pharmacol Res, February 2018) |
|
Targeting few to help hundreds: JAK, MAPK and ROCK pathways as druggable targets in atypical chroni myeloid leukemia |
|
| January 2018 | |
| Dasatinib dose management for the treatment of chronic myeloid leukemia (Talpaz M et al. Cancer, January 2018) (epub ahead of print) |
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors (Alhuraiji A et al. Am J Hematol, January 2018) |
| Dasatinib-induced pulmonary arterial hypertension – A rare late complication (Ibrahim U et al. J Oncol Pharm Pract, January 2018) (epub ahead of print) |
Monitoring of leukemia stem cells in chronic myeloid leukemia patients (Cui J et al. Leuk Lymphoma, January 2018) (epub ahead of print) |
|
Dasatinib-induced pulmonary arterial hypertension |
Altered intracellular signaling by imatinb increases the anti-cancer effects of tyrosine kinase inhibitors in chronic myelogenous leukemia cells (Hirao T et al. Cancer Sci, January 2018) |
|
Will tyrosine kinase inhibitors be part of the treatment armamentarium for CML in the future? |
Lithium, a classic drug in psychiatry, improves nilotinib-mediated antileukemic effects |
| Monitoring TKI therapeutic responses with the panel of metabolic biomarkers in the chronic myeloid leukemia patients (Yang B et al. Cancer Sci, January 2018) (epub ahead of print) |
Dual drug targeting of mutant BCR-ABL induces inactive confirmation: |
|
Racial differences in four leukemia subtypes: Comprehensive descriptive epidemiology |
|
|
Antitumor effects of blocking protein neddylation in T3151-BCR-ABL leukemia cells and leukemia stem cells |
|
|
Blockage of endoplasmic reticulum attenuates nilotinib-induces cardiotoxicity by inhibition of the Akt-GSK3ß-Nox4 signaling |
|
|
Effects on antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells |
|
| Therapeutic targeting of CK2 in acute and chronic leukemias (Buontempo F et al. Leukemia, January 2018) |
|
| December 2017 | |
| Treatment-free remission in CML: who, how, and why? (Mahon FX. Hematology Am Soc Hematol Educ Program, December 2017) |
Exosomes derived from imatinib-resistant chronic myeloid leukemia cells mediate a horizontal transfer of drug-resistant trait by delivering miR-365 (Min QH et al. Exp Cell Res, December 2017) (epub ahead of print) |
| Cardiovascular care of patients with chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) therapy (Barber MC et al. Hematology Am Soc Hematol Educ Program, December 2017) |
Ecotopic viral integration site 1 (EVL1) transcriptionally targets talin 1 (TLN1) and upregulates its expression in chronic myeloid leukemia (Halder A et al. Leuk Lymphoma, December 2017) (epub ahead of print) |
| Novel approaches to therapy in CML (Bhatia R et al. Hematology Am Soc Hematol Educ Program, December 2017) |
C1206, a novel curcumin derivate, potently inhibits Hsp90 and human chronic myeloid leukemia cells in vitro (Fan YL et al. Acta Pharmacol, December 2017) (epub ahead of print) |
| Front-line treatment options for chronic-phase chronic myeloid leukemia (Shah NP et al. J Clin Oncol, December 2017) (epub ahead of print) |
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib (Giallongo C et al. J Cell Mol Med, December 2017) (epub ahead of print) |
| Mechanisms of resistance to targeted therapies in chronic myeloid leukemia (Lussana F et al. Handb Exp Pharmacol, December 2017) (epub ahead of print) |
Controversies regarding use of myeloid growth factors in leukemia (Poston JN et al. J Natl Compr Canc Netw, December 2017) |
| Management of chronic myeloid leukemia in the setting of pregnancy: when is leukocytapharesis appropriate? A case report and review of the literature (Staley EM et al. Transfusion, December 2017) (epub ahead of print) |
|
|
Atypcial chronic myeloid leukemia: a rare entity with management challenges (Dhakal P et al. Future Oncol, December 2017)(epub ahead of print) |
|
|
Successful ovarian stimulation for fertility preservation in a patient with chronic myeloid leukemia: switch from nilotinib to interferon-alpha |
|
CML Publications 2014-2017
Access 2017 CML publications here
Access 2016 CML publications here
Access 2015 CML publications here
Access 2014 CML publications here
Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!
Search for more publications on CML at PubMed.gov
An Expert Opinion: Interferon and CML during the COVID-19 Pandemic
Over the last few days, reports of the possible efficacy of interferon in treating COVID have emerged.1,2 This needs some clarity for CML patients as there are different interferons.
With a long standing history of treating CML with interferon, the question has been raised as to whether patients on interferon have more resistance to COVID and even if patients are on tyrosine kinase therapy, should we be switching them to interferon. As can be seen at other places on the iCMLf website, it is not at all clear that CML patients are more at risk for COVID than the general population or whether they will have worse outcome infections if they do get the viral infection.
Secondly, as is reviewed in the papers by Talpaz et al and Cayssials et al, alpha-interferon is active against CML either alone or in combination.3,4 This is a different drug than the beta-interferon used in the Lancet studies quoted above.1,2 Beta-interferon has no significant activity against CML. The most common use of beta-interferon has been in the therapy of multiple sclerosis. Gamma-interferon, which showed some activity against CML, has never really been put into clinical use for any disease.
A paper by Almeida et al, actually describes two MS patients who developed CML while on therapy with beta-interferon.5
In a review by Ahsan et al on the possible therapy for COVID19, a number of drugs have been discussed.6 The use of inhaled alpha-interferon in prophylaxis of corona viruses has been discussed. The idea of using this application to prevent respiratory viruses was abandoned decades ago because of convenience and cost.
In summary, the beta-interferon work in the therapy of COVID-19 needs additional study but is tantalizing. By no means however, should CML patients consider interferon as an option to replace TKI therapy other than very limited indications, such as combination therapy studies, TKI intolerance or pregnancy and then only under the strict guidance of a knowledgeable physician experienced with the use of alpha-interferon.
Professor Jeff Lipton
Princess Margaret Hospital
Toronto, Canada
References
- Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomized, phase 2 trial. Hung IF, et al Lancet. 2020 May 8. pii: S0140-6736(20)31042-4. doi: 10.1016/S0140-6736(20)31042-4. [Epub ahead of print]
- Interferon beta-1b for COVID-19. Shalhoub S. Lancet. 2020 May 8. pii: S0140-6736(20)31101-6. doi: 10.1016/S0140-6736(20)31101-6. [Epub ahead of print] No abstract available.
- The interferon-alpha revival in CML. Talpaz M, Mercer J, Hehlmann R. Ann Hematol. 2015 Apr;94 Suppl 2:S195-207. doi: 10.1007/s00277-015-2326-y. Epub 2015 Mar 27. Review
- Beyond tyrosine kinase inhibitors: Combinations and other agents. Cayssials E, Guilhot F. Best Pract Res Clin Haematol. 2016 Sep;29(3):271-283. doi: 10.1016/j.beha.2016.10.017. Epub 2016 Oct 20. Review.
- Chronic myeloid leukaemia in two multiple sclerosis patients on interferon beta-1a. Almeida L, Neves M, Cardoso E, Melo A. J Clin Pharm Ther. 2009 Feb;34(1):125-7. doi: 10.1111/j.1365-2710.2008.00983.x.
- Treatment of SARS-CoV-2: How far have we reached? Ahsan W, Javed S, Bratty MA, Alhazmi HA, Najmi A. Drug Discov Ther. 2020 May 6;14(2):67-72. doi: 10.5582/ddt.2020.03008. Epub 2020 Apr 25. Review.
More papers on COVID-19
March 2020
- COVID-19 and the cardiovascular system
Zheng YY et al. Nat Rev Cardiol, March 2020 (epub ahead of print) - open access publication - Challenges of coronavirus disease 2019
Lancet Infect Dis, March 2020 - open access publication
February 2020
- Clinical characteristics of coronavirus disease 2019 in China
Guan W et al. N Eng J Med, February 2020 - open access publication - Q&A: The novel coronavirus outbreak causing COVID-19
Fisher D & Heymann D et al. BMC Medicine, February 2020 - open access publication - Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies
Ahmed SF et al. Viruses, February 2020 - open access publication - Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang C et al. Lancet, February 2020 - open access publication - Update: Public health responses to the coronavirus disease 2019 outbreak - United States, February 24, 2020
Jernigan DB & CDC COVID-19 Response Team, MMWR Morb Mortal Wkly Rep, February 2020
- open access publication - Coronavirus disease 2019 (COVID-19) and pregnancy: What obstetricians need to know
Rasmussen SA et al. Obstet Gynecol, February 2020 (epub ahead of publication) - open access publication - The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020
The novel Coronavirus Pneumonia Emergency Response Epidemiology Team, Center of Disease Control (CDC) China Weekly
More papers on COVID-19 and CML
May 2020
- Frequently asked questions regarding SARS-CoV-2 in cancer patients – recommendations for clinicians caring for patient with malignant diseases
von Lilienfeld-Toal M et al. Leukemia, May 2020 (epub ahead of print)
- open access publication - Two false-negative test results in a symptomatic patient with a confirmed case of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and suspected Stevens-Johnson Syndrome / toxic epidermal necrolysis (SJS/TEN)
Langziel T et al. Cureus, May 2020 – open access publication - COVID-19 in persons with chronic myeloid leukaemia
Li W et al. Leukemia, May 2020 (epub ahead of print) - open access publication - COVID-19 and cancer: A comprehensive review
Gosain R et al. Curr Oncol Rep, May 2020 - open access publication - SARS-CoV-2 (COVID-19) and chronic myeloid leukemia (CML): a Case Report and Review of ABL kinase involvement in viral infection
Abruzzese E et al. Mediterr J Hematol Infect Dis, May 2020 - open access publication - Chronic myeloid leukaemia and the use of tyrosine kinase inhibitors in the days of COVID-19 pandemic
Eskazan AE et al. Br J Clin Pharmacol, May 2020 (epub ahead of print) - open access publication - Treating leukemia in the time of COVID-19
Paul S et al. Acta Haematol, May 2020 (epub ahead of print) - open access publication - The CoV-2 outbreak: how hematologists could help to fight COVID-19
Galimberti S et al. Pharmacol Res, May 2020 (epub ahead of print) - open access publications - Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomized, phase 2 trial
Hung IF et al. The Lancet, May 2020 – open access publication - Successful prevention and screening strategies for COVID-19: focused on patients with hematological diseases
Cho SY et al. Br J Haematol, May 2020 - open access publication
April 2020
- Hematology in the time of COVID-19
Gavillet M et al. Rev Med Suisse, April 2020 (in French) - COVID-19 in persons with hematological cancers
He W et al. Leukemia, April 2020 (epub ahead of print) - Effect of the COVID-19 pandemic on cancer treatment and research
Saini KS et al. Lancet Haematol, April 2020 (epub ahead of print) - What the oncologist needs to learn about COVID-19 infection in cancer patients
Rassy E et al. Future Oncol, April 2020 (epub ahead of print) - open access publication
March 2020
- The first report of the prevalence of COVID-19 in chronic myelogenous leukemia patients in the core epidemic area of China: multicentre, cross-sectional survey
Wang DY et al. MedRxix, March 2020 (epub ahead of print) - open access publication - Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China
Liang W et al. Lancet Oncol, March 2020 - open access publication - Coronavirus disease COVID-19: EBMT recommendations update March 23, 2020
European Society for Blood and Marrow Transplantation (EBMT), March 2020 - open access publication
March 2018
- Coronavirus S protein-induced fusion is blocked prior to hemifusion by Abl kinase inhibitors
Journal of General Virology 2018;99:619–630 - open access publication
